GRPH

ANALYST NOTE: GRPH (Graphite Bio, Inc.) Date: 2026-06-13 Current Price: $22.26

1. Structural Readiness

Conservative Entry: Not yet defined (awaiting breakout confirmation) Aggressive/Pre-Breakout Entry: N/A (Current price is $22.26; no specific breakout level defined in current data) Breakout Level: Not yet defined. Extension: Not applicable (Price has not broken out). ATR Context: Current ATR is 9.7% (Extreme). This indicates high volatility and elevated risk of severe drawdowns if the setup fails.

2. Thesis Layer

Thesis Classification: TACTICAL / Setup-Led Macro Thesis: None. Reasoning: As of 2026-06-13, there is no named secular thesis driving this name. The investment case is strictly tactical, relying on the quality of the technical setup (the forming coil) and the immediate business fundamentals (revenue traction and cash runway). We are not assigning a macro theme (e.g., "Gene Editing Boom" or "Ophthalmic Growth") to this trade. The conviction must be derived entirely from the setup quality and the company's ability to execute its current commercial launch.

3. Business Analysis

Company Overview: Graphite Bio, Inc. operates as a clinical-stage gene editing company with a dual focus: a commercialized ophthalmic product and a pipeline of gene therapies for severe genetic diseases.

Commercial Business (VIZZ): The company has successfully launched VIZZ, a prescription treatment for presbyopia.

• Revenue & Volume: As of Q1 2026 (reported May 11, 2026), the company generated $1.9 million in net revenue, including $1.7 million in product sales.
• Adoption Metrics: The company delivered approximately 25,000 paid and filled prescriptions in Q1 2026, representing a 19% increase compared to Q4 2025. Total monthly units sold since launch reached roughly 46,000.
• Physician Base: There are over 10,000 unique prescribers, with new prescribers writing for the first time daily.
• Consumer Behavior: A consumer survey indicated that 50% of VIZZ users previously used contact lenses as their primary vision correction, validating a large, addressable market.
• Retention: Over 2/3 of e-pharmacy volume now comes from 3-month prescriptions, indicating strong repeat purchase behavior compared to Q4.
• Efficiency: At this stage of launch, VIZZ is generating roughly 30% more scripts per prescriber than the company's previous product, VUITY, across all prescribing deciles.

Pipeline Business (Gene Editing): The company maintains a pipeline of investigational gene-edited therapies:

• GPH101: An autologous, gene-edited hematopoietic stem cell product for sickle cell disease.
• GPH201: Intended for X-linked severe combined immunodeficiency syndrome (SCID).
• GPH301: An experimental candidate for Gaucher disease.

Financial Position: As of Q1 2026, the company held $258.4 million in cash, cash equivalents, and marketable securities. The Q1 2026 net cash burn was approximately $34 million, which was consistent with Q4 and in line with the company's budget.

4. Archetype and Conviction

Archetype: Deep Value Recovery Fit Analysis: The "Deep Value Recovery" archetype fits because the company has moved from a pure clinical-stage biotech to a commercial entity with tangible revenue ($1.9M) and a clear path to scaling (19% QoQ growth in scripts). The "value" component is derived from the cash runway ($258.4M) relative to the burn rate ($34M/quarter), providing a runway of approximately 7.5 quarters without additional dilution, assuming the burn remains constant. The "recovery" aspect is the transition from pre-revenue to revenue-generating, supported by the strong initial adoption metrics (30% higher scripts per prescriber vs. VUITY).

Valuation & Financial Spine:

The financial spine indicates the company is still in a loss-making phase, consistent with a biotech in the commercialization ramp-up. The negative EPS is expected given the R&D and commercialization costs.

• Forward Consensus EPS (FY1): -0.4
• Forward Consensus EPS (FY2): -0.4
• Coverage: Complete.

Conviction Stack:

• Thesis Strength: Low (No macro thesis; purely tactical).
• Evidence Quality: High. The earnings transcript provides specific, quantifiable data on revenue, prescription volume, and physician adoption.
• Structural Quality: Moderate. The setup is "Forming," meaning the technical structure is present but unconfirmed. The extreme ATR (9.7%) is a significant negative factor, indicating high volatility and potential for false breakouts or sharp reversals.
• Setup Readiness: Partial. The coil is forming, not confirmed.
• Rerating Potential: Moderate. If the commercial ramp continues and the technical breakout occurs, the market may re-rate the company from a "clinical-stage" to a "commercial-stage" valuation.

5. Invalidations, Strengths, and Gaps

What Would Invalidate the Case:

• Fundamental: A significant deviation from the $34M quarterly burn rate (e.g., a spike to $50M+) or a failure to maintain the 19% QoQ growth in prescriptions would undermine the "Deep Value Recovery" thesis.
• Operational: A drop in the 3-month prescription retention rate (currently >66%) would signal weak product stickiness.

What Would Strengthen the Case:

• Technical: A confirmed breakout above the resistance structure with volume, moving the coil from "Forming" to "Confirmed-Active."
• Fundamental: Management guidance indicating a reduction in cash burn or an acceleration in prescription growth beyond the 19% QoQ trend.
• Pipeline: Positive data readout from GPH101 or GPH201, which would add a second growth engine to the commercial revenue.

Gaps in Evidence:

• Guidance: The provided evidence does not include specific forward-looking guidance for Q2 2026 or full-year 2026 revenue targets.
• Margin Trajectory: There is no data on gross margins for VIZZ or the specific R&D spend allocation for the pipeline in the provided transcript.
• Competitive Landscape: No specific data on competitor pricing or market share dynamics beyond the internal comparison to VUITY.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: low Key evidence: 1. Q1 2026 revenue of $1.9M with 19% QoQ prescription growth. 2. Strong retention metrics with >66% of e-pharmacy volume from 3-month prescriptions. 3. Robust cash position of $258.4M providing ~7.5 quarters of runway at current burn. Key risks: 1. Extreme ATR of 9.7% indicates high volatility and severe drawdown risk. 2. Setup is "Forming" with no confirmed breakout, making it unactionable on technicals alone. 3. Company remains unprofitable with negative forward EPS consensus. Sizing hint: Position size should be minimal due to extreme volatility and unconfirmed technical setup; treat as a satellite holding pending breakout confirmation. Expected path: Management expects continued ramp in prescription volume and stable cash burn; technical structure requires a breakout above resistance to confirm the "Deep Value Recovery" thesis. Expected horizon: 3 to 6 months for the technical setup to resolve (breakout or invalidation) and for commercial data to validate the growth trajectory.